Targeted therapy for ovarian cancer – case report
MUDr. Mária Zvariková
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Treatment of epithelial ovarian cancer is historically based on surgery and platinum doublet chemotherapy and is associated with high risk of relapse and poor prognosis in recurrent disease. Innovative treatment with PARP inhibitors has demonstrated an outstanding activity in epithelial ovarian cancer and is currently changing clinical practice in patients with BRCA mutation in genes.
ovarian cancer, PARP inhibitor, olaparib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...